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Abstract
Demyelinating diseases of the central nervous system (CNS), such as multiple sclerosis 
(MS), are characterized by multiple focal demyelinating lesions, resulting in various func-
tional deficits. The pathology of MS is defined by local loss of myelin sheaths in the brain 
and spinal cord associated with infiltration of peripheral immune cells. Classically, MS 
starts with a series of relapses and remissions, followed several years later by a more 
progressive form of the disease and a steady functional decline. Although the mechanism 
of disease initiation is poorly understood, disease progression is associated with immune 
system activation toward CNS antigens including myelin proteins. Animal models of 
MS have been critical in the development of MS therapies, with experimental allergic 
encephalitis (EAE) being the most common. This model has been instrumental in defin-
ing the role of T cells in disease progression and in the development of targeted thera-
pies. Understanding the biology of myelin repair has, however, largely come from other 
model systems including local targeted demyelination in vivo, slice preparations, and 
in vitro. This has led to the identification of a diverse array of potential new targets to 
modulate disease progression. Development of these new avenues is the target of inten-
sive ongoing research.
Keywords: remyelination, therapeutics, animal model, multiple sclerosis, 
oligodendrocytes, astrocytes, experimental allergic encephalitis (EAE)
1. Introduction
Myelin is the fatty insulation that surrounds axons, enhances axonal conduction rates, and 
protects axons from damage in the nervous system. In the central nervous system (CNS), 
the majority of myelin is a product of oligodendrocytes, and a single oligodendrocyte may 
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myelinate multiple segments of different axons. During development, oligodendrocytes are 
generated from precursors (OPCs—oligodendrocyte precursor cells) that arise in specific 
locations of the brain and spinal cord as a result of local inductive cues (discussed in more 
detail later). While oligodendrocytes and myelin are found throughout the CNS, the amount 
of myelin in white matter is substantially greater than that in gray matter. Indeed, the primary 
reason that white matter appears white is due to its high concentration of lipid-rich myelin. 
Because myelin plays a central role in modulating neuronal activity, its loss is frequently 
associated with functional deficits. Myelin loss or demyelination occurs in various different 
pathological conditions including developmental disorders such as the leukodystrophies, 
adult-onset insults such as stroke, and classical demyelinating diseases such as multiple scle-
rosis (MS) and related disorders. MS, the most common CNS demyelinating disease, was 
originally described over 100 years ago, and initial descriptions of the disease highlighted 
an illness of increasing functional deficits. Our understanding of the disease course and its 
progression has advanced over time, and it is now clear that MS is a more complex disorder 
in terms of clinical presentation and underlying pathogenesis [1–6].
In classic cases, MS initially presents as a sudden-onset neurological deficit that resolves over 
a period of time. Subsequent attacks (relapses) are followed by periods of remission; however, 
over time, remission fails to result in a return to normal functionality and deficits slowly accu-
mulate. Following this relapsing-remitting phase (relapsing-remitting MS), the disease enters 
a more chronic phase in which deficits accumulate in a progressive manner (progressive MS) 
(Figure 1). Not all patients follow this disease trajectory. In a distinct subset of patients, the 
Figure 1. Graph showing typical disease activity in relapsing remitting MS, characterized by defined clinical attacks 
followed by full functional recovery (A) or incomplete recovery between attacks with residual deficits (B), eventually 
leading to worsening disability (C).
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disease presents initially as progressive functional impairment without obvious remissions—
a condition known as primary progressive MS. Alternatively, some patients never progress 
beyond the relapsing remitting phase, and others only experience a single attack. In MS and 
numerous MS-related conditions, myelin loss is localized and multiple areas of demyelination 
or plaques may be present in a single patient. Each of the plaques appears to progress or 
resolve independently during the progression of the disease.
The variability in presentation and progression makes the accurate diagnosis of MS compli-
cated [6]. This is further compounded by the lack of biomarkers that unambiguously iden-
tify MS, and consequently, a diagnosis of MS is dependent on several factors in an overall 
presentation rather than a single definitive test. Identifying factors include medical history 
and clinical examination, magnetic resonance imaging (MRI) imaging, and the presence 
of oligoclonal bands in CSF. While MRI and other imaging modalities are highly effective 
at identifying lesions in CNS white matter, they are not able to specifically characterize 
MS-associated demyelinated lesions, and other conditions such as inflammation may gener-
ate similar MRI findings. Recent advances in imaging modalities have enhanced the specific-
ity of these approaches for demyelination, and it seems likely that more specific approaches 
will be implemented in the clinic in the near future. One such approach is using PET imaging 
to detect areas of myelin loss [7]. The development of selective tracers of myelin that can be 
visualized in a noninvasive manner is promising; however, the widespread application of this 
approach is likely to be limited by the short half-life of the probes and the necessity of a local 
cyclotron for their production.
While generally considered to be a disease of white matter, and myelin in particular, there is 
now strong data indicating that MS plaques also occur in gray matter, including synapses, 
and that altered synaptic transmission along with loss of gray matter may contribute to cogni-
tive deficits and brain atrophy often associated with MS [8]. Wherever they occur, MS plaques 
are frequently associated with a core blood vessel and reactive astrocytes. The close associa-
tion of blood vessels with MS plaques is indicative of the role of the immune system in the 
pathogenesis of MS, which is universally recognized as an autoimmune disease. Considerable 
evidence indicates that T cells that recognize myelin antigens enter the CNS and attack myelin 
and oligodendrocytes. This inflammatory insult recruits other cells including cells of the 
innate immune system such as macrophages and microglia that contribute to CNS damage. 
The majority of existing MS therapies are directed toward either suppressing the immune 
response or blocking the entry of T cells and other cells of the peripheral immune system 
into the CNS. While such approaches have been quite effective at modulating the severity 
and interval of relapses in relapsing remitting MS, it has become clear that they fail to block 
overall progression of the disease and brain atrophy, and neurodegeneration is only slightly 
improved. Such observations have led to a concerted effort to identify therapies for MS that 
are targeted toward promoting myelin repair or inhibiting damage within the CNS but have 
been somewhat hampered by the lack of understanding of the causes of MS.
The chronic nature of MS and the likelihood that the disease has been ongoing for an extended 
interval prior to becoming symptomatic make it extremely difficult to identify the initial 
pathogenic signal. One attractive hypothesis is that a potential trigger for MS is a response to 
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a prior infection or other environmental signal [9]. This notion is supported by the findings 
that MS patients have elevated immunological responses to various pathogens, which may 
account for some aspects of the epidemiology of MS. A wide range of pathogens including 
spirochetes, chlamydia, and a range of viruses have been linked to MS [1]. It seems likely that 
the role of such pathogens is to enhance susceptibility to MS rather than directly induce dis-
ease. One of the strongest links in MS is viral infection [10], and a number of different viruses 
have been implicated including Epstein-Barr, human herpes virus 6, and human endogenous 
retroviruses [10–12]. Precisely how the viral infection contributes to MS development has not 
been clarified, but it may reflect the initial stimulation of immune cells to viral antigens or the 
induction of oligodendrocyte death as a result of viral infection.
One aspect of MS that has been extensively studied is its genetic linkage [13], and instead of a 
gain or loss of function of one individual gene, there are a range of genetic associations linked to 
MS. In particular, MHC class 11 molecules such as HLA-DR and HLA-DQ alleles are considered 
risk factors for the disease [14]. Given the immunological nature of the disease, the association 
with immunomodulatory genes is expected; however, the mechanisms by which these genetic 
changes increase disease susceptibility are still unclear. For example, certain MHC molecules 
can promote the development of an autoimmune response following a sub-acute challenge from 
a structurally similar antigen. The contribution of genetic or epigenetic changes in cells of the 
oligodendrocyte lineage or myelin that contribute to MS susceptibility remains to be clarified.
To understand the biology of MS requires a clear understanding of the cellular and molecu-
lar mechanisms that mediate myelination and myelin maintenance, and much of our under-
standing of the control of myelination comes from studies in development. Oligodendrocytes, 
the myelinating cells of the CNS [15–18], are generated from precursor cells (OPC or oligo-
dendrocyte precursor cells) that arise in distinct location of the embryonic CNS in response to 
selective inductive cues and subsequently disperse throughout the CNS [17, 19–21]. The early 
commitment of neural stem cells to the oligodendrocyte lineage depends on environmental 
cues that include sonic hedgehog and the subsequent induction of transcriptional signaling 
pathways that promote the appearance of OPCs, their proliferation, and subsequent migration. 
One of the major mitogens and potential growth factors that support the expansion of the oli-
godendrocyte lineage is platelet-derived growth factor alpha (PDGFα). The receptor PDGFαR 
is expressed predominantly by OPCs in vivo and allows for the unambiguous identification 
of OPCs in the setting of demyelination and repair. In the spinal cord, OPCs originate at the 
ventral midline during embryonic development and subsequently disperse widely through 
gray and white matter. This migration is guided by a number of different signals including 
Netrin 1 and Wnts and appears to track with the vasculature. Prior to myelination, OPCs dif-
ferentiate to oligodendrocytes, a process that includes the cessation of proliferation and the 
induction of additional transcription factors including Myrf that are essential for oligodendro-
cyte maturation. The differentiation of oligodendrocytes is clearly environmentally regulated. 
For example, myelin debris has been shown to inhibit the differentiation of oligodendro-
cytes and may be an important factor in the control of remyelination where delayed myelin 
clearance may inhibit repair [22, 23]. Once oligodendrocytes mature, there is a defined time 
window during which they extend multiple processes to contact adjacent axons and initiate 
myelination. Less is known about the molecular interactions that orchestrate the initiation of 
Neuroplasticity - Insights of Neural Reorganization128
myelination. Several parameters such as axonal size and electrical activity have been impli-
cated as important in the early stages of myelination. In addition, several factors have been 
suggested to inhibit the onset of myelination, and these include LINGO-1 and the expression 
of PSA-NCAM on axonal surfaces. Following differentiation and maturation, oligodendro-
cytes begin to generate myelin sheaths. An individual oligodendrocyte initially generates an 
excess number of myelin sheaths, some of which grow and are stabilized, while others shrink 
and are subsequently lost. What regulates the growth and retraction of myelin sheaths is not 
well understood, but recent studies suggest that it may be regulated by axonal activity.
Myelin is a specialized plasma membrane that provides a fatty insulation around axons and 
allows the rapid conduction of electrical impulses by increasing conduction velocity, reducing 
the threshold for firing, and providing axonal protection [24]. Myelin sheaths are discontinu-
ous and are linked by Nodes of Ranvier (Figure 2) that have a characteristic morphology and 
are areas of high concentration of ion channels that support electrical impulse propagation. 
Nodes of Ranvier appear to be particularly sensitive to damage, and their disruption results in 
perturbation of axonal conduction. The region between two nodes is known as the internode, 
and it is made up of a number of specific proteins [25], including the major proteins myelin basic 
protein (MBP) and proteolipid protein (PLP) as well as other minor proteins such as myelin-
associated glycoprotein (MAG), myelin oligodendrocyte protein (MOG), 2’3’ cyclic nucleotide 
3’phosphdiesterase (CNP), and myelin-associated oligodendrocyte basic protein (MOBP) [26]. 
Figure 2. CNS myelin. Schematic representation of an oligodendrocyte ensheathing several axons in the CNS. Segments 
of myelin sheaths are separated by Nodes of Ranvier, which are contacted by astrocyte foot processes.
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Each of these myelin components is presumably important for normal myelin function. For 
example, MBP mutant animals such as shiverer fail to form compact myelin and have limited 
life span [27], while animals lacking PLP develop normally but manifest axonal pathology 
later in life [28, 29].
The normal development of myelin is also dependent on additional CNS cell types: axonal 
processes are targets for myelination, and astrocytes are important in the development and 
survival of cells of the oligodendrocyte lineage [30]. Astrocytes are a heterogeneous cell popu-
lation that have been proposed to perform multiple functions that support development and 
maintenance of the brain and spinal cord. During development, astrocytes guide the migra-
tion of neurons from their germinal zones to their final destination [31] and act as substrates 
for long-distance axonal growth to their targets. In the adult, astrocytes are important for 
the removal of neurotransmitters, control of the ionic environment, and maintenance of the 
blood-brain barrier as well as either supporting or inhibiting regeneration through the forma-
tion of glial scars [32–34] that are comprised of astrocyte processes and extracellular matrix. 
A similar glial scar is formed around chronic demyelinating lesions and has been suggested 
to block myelin repair [35], although recent studies indicate that the astrocyte response is 
beneficial in certain animal models.
Histological studies provide an evidence of neuronal damage in MS, including axonal loss 
in areas of demyelination [29, 36] or even frank brain atrophy due to widespread loss of 
neuronal cell bodies and their axons [37]. It is unclear whether the axonal loss is secondary 
to myelin loss or independent of it via direct antigenic targeting. The role of astrocytes in MS 
disease pathogenesis is less well defined. For example, in areas of demyelination, a reactive 
astrocytic response is commonly characterized by elevated expression of glial fibrillary acidic 
protein (GFAP) that may be either protective or pathogenic [38]. Disruption of the blood-
brain barrier is also important in the formation of demyelinating lesions in MS, and astro-
cytes have been proposed to play an important role in the maintenance of the blood-brain 
barrier in the adult CNS. The best evidence for an astrocytic role in demyelination comes 
from the studies of the MS variant known as neuromyelitis optica (NMO) that preferentially 
presents in the optic nerve and spinal cord. In a significant subset of NMO patients, demy-
elination is thought to result from the binding of pathogenic antibodies against aquaporin 4, 
a molecule expressed on the end feet of astrocytes around blood vessels. Antibody binding 
results in astrocyte death and subsequent demyelination, although the molecular linkages in 
this cascade are unknown.
The cellular complexity and heterogeneity of MS-like diseases represent a significant 
challenge in developing effective animal models that accurately mimic disease pro-
gression, and this has led to the generation of a number of different models, each of 
which highlights distinct components of the disease [39]. Some of the most powerful and 
best-studied models of MS are those that utilize selective stimulation of the peripheral 
immune system as the major driver of CNS pathogenesis, and these are discussed in more 
detail later.
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2. Animal models of demyelinating diseases: strengths and 
weaknesses
2.1. Immunological models for CNS demyelination
Multiple sclerosis is characterized by the engagement of the immune system, and this has 
been primarily modeled through approaches collectively known as experimental allergic 
encephalitis (EAE) [40, 41]. In general, EAE is an inflammation-mediated demyelinating dis-
ease that is induced in host animals through immunization with CNS tissue resulting in a host 
of functional deficits that correlate with immune cell infiltration into the CNS. The functional 
deficit is then scored on a 1–5 scale: 1 presents with a flaccid tail, 2 with hindlimb weakness, 
3 with hindlimb paralysis, 4 with forelimb and hindlimb paralysis, and 5 death. In most stud-
ies, the scale is expanded to between 2.5 and 3.5, allowing for better definition of functional 
changes.
Initial development of EAE involved injection of spinal cord homogenates into rabbits result-
ing in hindlimb paralysis and other functional deficits. Subsequently, immunization of mon-
keys with spinal cord homogenate derived from rabbit CNS [42] showed the pathological 
accumulation of cells around blood vessels of the brain and spinal cord. Variability in individ-
ual animal responses limited initial studies; however, this has largely been resolved through 
the use of immune stimulants such as complete Freund’s adjuvant (CFA) combined with 
pertussis toxin. This model has been refined through identification of effective protein anti-
gens. These antigens are predominantly myelin-associated proteins including myelin basic 
protein (MBP), myelin-oligodendrocyte glycoprotein (MOG), and proteolipid protein (PLP) 
[41]. Minor myelin components are also capable of generating disease suggesting that most 
myelin components can act as effective priming antigens. The identification of specific myelin 
protein peptides that provoke a reproducible and consistent disease following immunization 
into genetically defined host populations has resulted in several major models of EAE that are 
now commonly used. These include the induction of EAE in the SJL mouse genotype follow-
ing immunization with the PLP
139-151
 peptide, which generates a relapsing remitting disease 
mimicking some characteristics of relapsing remitting MS. An alternative model utilizes C57/
Bl6 mice immunized with the MOG peptide
35-55
. This model is often used to recapitulate more 
advanced stages of MS because it generates a more chronic disease course. Other less com-
mon models include the induction of EAE in PL/J mice following immunization with MBP 
or MOBP and immunization of Biozzi ABH mice with MOG protein that models selective 
aspects of MS.
Several major themes have emerged from studies on the mechanisms of disease in murine 
EAE. One common finding is a primary role for T cells in disease development. Adoptive 
transfer clearly demonstrated that T cells specific for MBP antigen were capable of transfer-
ring disease to naïve hosts [43]. The functional deficits in this model were transient, resolv-
ing within 1–2 weeks, and were not characterized by extensive demyelination suggesting the 
pathology in MS reflects multiple pathogenic processes. One strong candidate that contributes 
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to EAE and MS pathology is B cells [44]. B cells play multiple roles in immune-mediated 
pathology in the CNS. On the one hand, they facilitate activation and expansion of T cell 
populations within the CNS and enhance the recruitment of other immune cells into the CNS.
On the other hand, B cells produce antibodies directed against the different myelin antigens. 
For example, some MS lesions are characterized by an overexpression of anti-myelin anti-
bodies, with MOG as a potential antigenic target [45]. Understanding the roles of B cells in 
the underlying pathogenesis of MS and other neuro-inflammatory diseases now seems to 
be at the forefront of research development after demonstrating that two B-cell inhibitors, 
Rituximab and Ocrelizumab, were shown to be highly effective in some MS patients, includ-
ing those with primary progressive MS [46–48].
The role of the innate immune system in demyelinating pathologies is also an area of cur-
rent focus. Microglial cells are also known to undergo reactive changes, whereby they aid in 
myelin clearance, but also could potentially participate in antigen presentation along with 
dendritic cells. One hypothesis is that pathological mechanisms vary by the stage of disease. 
Relapsing remitting disease, for example, may be largely driven by influx from the peripheral 
adaptive immune cells, whereas secondary and primary progressive forms of the disease are 
largely driven by the innate immune system.
Myelin components are not the only antigenic targets in MS. For example, axon-specific pro-
teins, such as the neurofilament triplet, and node of Ranvier components, such as Contactin/
TAG-1 and S100, have also been associated with EAE and MS [49]. It is unclear, however, 
whether the aforementioned proteins are primary disease targets or their involvement is 
secondary to myelin loss. It is likely, however, that as the disease progresses, the ongoing 
destruction of neural tissue expands the pathological basis of the disease resulting in more 
widespread damage and worsening functional deficits.
EAE models have been invaluable in elucidating critical aspects of MS biology and other demy-
elinating CNS diseases and have been reviewed in detail [40, 41]. One of the major advantages 
is that EAE utilizes well-defined antigenic targets and can be adaptable to numerous genetic 
animal models. This has allowed the identification of several well-defined networks resulting 
in T cell activation and trafficking, as well as shed light into the role of T cell subsets in disease 
progression. What is important is that these disease models still serve as primary tools not 
only for disease modeling but also for validating and identifying new therapeutic targets.
Another aspect of MS pathology that has started to gain ground is the effect on long-term syn-
aptic plasticity, which is the physiological mechanism responsible for learning and memory 
and also is a key determinant of clinical recovery after cortical injury. It has now become clear 
that MS is frequently associated with cognitive and behavioral changes, which have been 
detected in the early stages of the disease, and are certainly more common than previously 
thought [50]. These changes are likely the result of synaptic impairment or altered synaptic 
plasticity. Among the different brain regions, the hippocampus is the most vulnerable. Despite 
its obvious importance, very few studies have been directed at understanding the hippocampal 
synaptic plasticity after EAE and not all are in agreement with what effect EAE has on hip-
pocampal long-term synaptic plasticity. There is, however, sufficient evidence to indicate that 
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activated microglia are responsible, and that changes in synaptic plasticity are rather dynamic, 
effectively mirroring the stages of the disease and severity of inflammation. Along those lines, 
it has also been suggested that enhanced cortical plasticity is predictive of functional recovery 
after a relapse [51].
An important variant of immune-mediated models of demyelination is the generation of local 
rather than systemic lesions [52]. This has been achieved by sensitizing host animals with sub-
threshold levels of encephalogenic peptides and subsequently delivering a local injection of a 
pro-inflammatory cytokine to stimulate local demyelination. For example, injection of 
1–125
MOG 
peptide and incomplete Freund’s adjuvant into Lewis rats results in an immune response but 
no overt clinical symptoms. Subsequent local injection of tumor necrosis factor alpha (TNF-α) or 
interferon-gamma (INF-γ) results in localized infiltration of immune cells, local demyelination, 
and axonal damage. Such studies revealed a rapid local functional deficit reflecting immune-
mediated damage. This was followed by some functional recovery, although axonal damage 
remained. There are several strengths to this model including the ability to assess long-term con-
sequences of a localized immune response and the capability to develop novel therapies to mod-
ulate initial immunological insult and promote long-term functional recovery. Such a model has 
several weaknesses including the localized nature of the insult and the method of induction of 
inflammatory stimuli. Local injection of cytokines results in damage to the blood-brain barrier 
and the stimulation of a robust astroglial response making mechanistic interpretation of the 
outcome of these studies difficult. There are a number of important differences between MS and 
EAE. EAE is generated through injection of selected antigens, while the trigger for MS is unclear. 
To date, there has been no description of a spontaneously occurring form of MS in animals. 
Second, the inclusion of unrelated antigens when inducing EAE has led to developing disease 
mechanisms and therapies that have otherwise failed clinical trials
Many of the current therapies used in the treatment of MS have emerged from studies of EAE, 
and it is not surprising that they are targeted toward regulation of immune cell responses. Such 
recent treatments include Fingolimod (FTY720) directed against the sphingosine-1-phosphate 
receptor that regulates T and B cell responses appears to directly stimulate remyelination 
in the CNS [53, 54], and Natalizumab directed toward adhesion molecules on lymphocytes 
blocks the entrance of those cells in the parenchyma of the CNS [55]. Such therapies, while 
modulating relapse activity, have generated unexpected side effects in the setting of clinical 
applications that have in certain cases limited their utilization. Furthermore, long-term stud-
ies suggest that while such therapies are effective at modulating inflammatory responses, they 
are less effective at controlling the disease activity or promoting recovery in the CNS. Current 
studies are becoming increasingly focused on developing approaches to promote myelin 
repair in the CNS, and EAE is not particularly suited to identification of repair mechanism.
2.2. Demyelination induced by gliotoxins
One of the major drawbacks of the aforementioned immune-mediated models of demyelin-
ation is that both pathological and repair processes occur simultaneously, which complicates 
the interpretation of potential repair strategies. To define the pathways mediating myelin 
repair, a variety of alternative models are available, and these include both focal and systemic 
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glial toxin treatments. These models, while they do not recapitulate the complex etiology and 
pathogenesis of MS, have two major strengths. First, the onset of the insult can be tightly regu-
lated in time and space; second, the epochs of demyelination and remyelination are largely 
separate, allowing for the characterization of molecular cues regulating each aspect of lesion 
generation and repair.
The most common model utilizes the generation of focal areas of demyelination induced by 
direct injection of chemicals that selectively ablate oligodendrocytes and their myelin. Many 
different demyelinating agents have been used, although the most common include lysoleci-
thin, ethidium bromide, and antibodies against the major sphingolipid component of myelin, 
galactocerebroside.
Lysolecithin (L-α-Lysophosphatidylcholine or LPC) when injected into white matter as a 1% 
solution induces focal demyelination [56, 57]. Common locations for LPC-induced lesions 
include spinal cord white matter, the midline of the corpus callosum, and caudal cerebellar 
peduncle. Injection of LPC results in a rapid loss of myelin and oligodendrocytes. Compared to 
other models, LPC lacks absolute cellular specificity, and there is a reduction in astrocytes and 
some axonal loss in the lesion. One powerful feature of LPC lesions is their ability to recover. In 
general, demyelination occurs rapidly, and the lesion area is largely devoid of myelin 2–3 days 
after lesion generation. Oligodendrocyte precursor cells repopulate the lesion sites around 
5 days and subsequently proliferate and differentiate into oligodendrocytes, with remyelin-
ation taking place between 7 and 14 days in rodents on average. The latter varies with the lesion 
site and animal age. By 30 days post-lesion, remyelination is essentially complete (Figure 3). 
These observations have led to the identification of several distinct molecular mechanisms, 
such as Notch and Wnt pathways, retinoid X receptor gamma signaling, growth factors such as 
hepatocyte growth factor and neuregulin, hormones including progesterone, cell cycle proteins 
such as cyclin-dependent kinases, chemokine receptors such as CXCR2, the NOGO receptor 
LINGO-1, and death receptor 6 (DR6) signaling. In white matter tracts containing large-caliber 
axons, the remyelinated axons have thinner myelin sheaths than the originals (Figure 3).
An alternative glial toxin, ethidium bromide results in cell loss due to its DNA-intercalating 
properties; therefore, all nucleated cells are affected in this model. Ethidium bromide is 
injected directly into white matter tracts, and the lesions tend to be larger than LPC lesions 
and have been utilized to assay the effects of age, sex, growth factors, and the role of microg-
lia/macrophage activation on remyelination. As expected, ethidium bromide injections cause 
a more widespread loss of astrocytes, oligodendrocytes, and OPCs while sparing axons. This 
is followed by the influx of macrophages in and around the lesion and the development of 
reactive astrocytosis, which aims to seal off the lesion site [58]. In contrast to LPC-induced 
lesions, a significant amount of remyelination in ethidium bromide-induced lesions in the spi-
nal cord is accomplished by Schwann cells. It was initially assumed that such Schwann cells 
were derived from peripheral nerves or spinal nerve roots adjacent to the lesion; however, fate 
mapping studies suggest that OPCs generate Schwann cells in the absence of astrocytes [59] 
raising the possibility that astrocyte regulate the fate of OPCs. Given the more widespread 
loss of neural cells, ethidium bromide lesions are less commonly used for the identification of 
remyelinating therapies.
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To provide enhanced cellular specificity, cell type-specific surface antibodies have been 
used to target the complement cascade and induce selective cell lysis [60]. This model has 
been effective using antibodies to galactocerebroside (GalC), the major myelin sphingolipid 
to eliminate mature oligodendrocytes. Initial studies demonstrated that a single intraspinal 
injection of complement proteins plus anti-GalC resulted in demyelination and partial loss of 
oligodendrocytes. Analysis of the mechanism of myelin repair suggested that it was the result 
of recruitment of OPCs and not Schwann cells or mature oligodendrocytes [61].
Figure 3. A) Representative image of dorsal spinal column cross section, stained with Toluidine blue, showing an LPC-
induced demyelinating lesions denoted by the asterisk. B) Representative high magnification image of an LPC lesion 
during remyelination. C) Graph depicting typical disease progression in a characteristic LPC lesion; including immune 
cell infiltra-tion around 3 days, followed by OPC recruitment peaking at 7 days, and then the onset of remyleination at 
apporximately 12 days post injection.
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A major strength of the local toxin models is that they provide a localized region of reproduc-
ible synchronized demyelination allowing for analysis of remyelination in the absence of con-
current demyelination. The timing of remyelination differs between the models, although all 
undergo spontaneous repair. Another advantage of using these models is their adaptability; 
lesions can be generated in animals of any age, at any accessible location, and from different 
genetic backgrounds. The disadvantage is that the mechanism of cell death is non-physio-
logic, and so whether this truly models naturally occurring lesion development, disease pro-
gression, and clinical phenotype is unclear. One particular aspect where these models have 
proven beneficial is the development of myelin-promoting therapies, as opposed to those 
modulating immune responses. For example, using an LPC-induced demyelination model, 
LINGO-1 was identified as a potential therapeutic target, whereby anti-LINGO-1 antibodies 
promoted OPC differentiation and subsequent remyelination [62, 63].
LINGO-1 knockout mice show precocious myelination, suggesting that LINGO-1 antagonists 
might be useful to accelerate myelin repair. Using both the LPC and cuprizone models (see 
below) of demyelination, anti-LINGO-1 antibody treatments significantly increase the speed 
of remyelination, suggesting a new therapeutic option for MS patients. The anti-LINGO-1 
Li81 antibody is the first MS therapy directly targeting remyelination and is currently in MS 
clinical trials.
A second commonly used approach for glial toxin-induced demyelination is systemic oral 
delivery of toxins that preferentially target oligodendrocytes. Systemic delivery of a glial 
toxin in a noninvasive manner has a number of advantages. For example, it overcomes the 
complexity associated with direct injections into the CNS and provides a larger demyelinat-
ing area allowing for easier molecular analysis. The most frequently utilized systemic toxin 
is cuprizone.
Ingestion of the copper chelator cuprizone (biscyclohexanone oxaldihydrazone) results in 
demyelination of specific brain regions, which is thought to reflect mitochondrial stress and 
an innate immune response [64]. Cuprizone-induced demyelination results from loss of oli-
godendrocytes rather than direct insults to myelin sheaths, and mice aged 6–9 weeks given 
0.2–0.3% cuprizone treatment of for 5–6 weeks develop acute demyelination of the corpus cal-
losum and other rostral white matter regions. Interestingly, the spinal cord is less susceptible, 
which could be in part due to a differential sensitivity by spinal oligodendrocytes to cupri-
zone, and/or nonuniform penetration in different CNS tissues. Oligodendrocyte apoptosis is 
also associated with extensive reactive astrogliosis and microglial activation. Acute demyelin-
ation is followed by spontaneous remyelination that occurs following removal of cuprizone 
from the diet. When cuprizone treatment is prolonged to 12 weeks or longer, remyelination is 
very sparse, resulting in a model of chronic demyelination.
The extended time course of disease induction and repair makes the cuprizone model use-
ful for studying the biological processes related to both demyelination and remyelination in 
the CNS. The cuprizone model has been extensively used to examine the potential of various 
compounds to stimulate myelin repair [65, 66]. Because the time course of cuprizone treat-
ment is so long, demyelination is progressive and remyelination begins while demyelination 
is still taking place. Combining cuprizone with rapamycin, which blocks mTor signaling, 
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decreases the efficiency of remyelination, making it easier to analyze and quantify repair pro-
cesses. The cuprizone model is easier to use compared to other models in that the toxin is 
included in regular mouse chow that is fed to the animals each day. There are, however, a 
number of concerns with this model. First, cuprizone is generally limited to mice, and there 
is a clear genetic linkage to the susceptibility for cuprizone toxicity. Likewise, there are dif-
ferences in susceptibility between gender and age that are poorly understood [67]; however, 
proof-of-principle studies demonstrate that signals known from in vitro studies to stimulate 
oligodendrocyte differentiation such as thyroid hormone (T3) promote remyelination in the 
cuprizone model, making it useful for therapeutic discovery.
2.3. Cell death models of demyelination
A number of studies have begun to suggest that demyelination may be a primary result of oli-
godendrocyte death, with activation of the immune system as a secondary event. Whether in 
the complex setting of disease damage to oligodendrocytes is direct or indirect likely depends 
on the immediate pathological conditions. An alternative cellular target that may trigger oli-
godendrocyte damage and demyelination is myelinated axons. Axonal damage and loss are 
frequently seen in MS lesions [36] and models of immune-mediated demyelination, although 
it is unclear whether axonal degeneration follows myelin loss or whether demyelination is 
a consequence of axonal degeneration. To distinguish between these possibilities, animal 
models in which oligodendrocytes are directly targeted for cell death are being developed 
to assess whether the loss of oligodendrocytes results in demyelination, how effectively and 
rapidly remyelination occurs, and whether localized demyelination results in axonal dam-
age. Information from such studies will help define new mechanisms of CNS pathology and 
novel targets for therapeutic intervention. Currently, there are three major ways for selec-
tively inducing oligodendrocyte cell death in the adult vertebrate CNS.
One approach to drive selective death of neural cells involves the selective expression of a 
toxic molecule targeted to specific cell types [68]. For example, extensive loss of oligoden-
drocytes has been achieved through the targeted expression of the alpha subunit of the 
diphtheria toxin (DT). Diphtheria toxin (DT) is composed of two subunits (alpha and beta), 
each having different functions. The beta subunit interacts with cell receptors to facilitate the 
entry of the toxin into the cell, whereas the alpha subunit is the cytotoxic component that acts 
intracellularly.
The cytotoxicity of DT results from inhibition of protein translation and cell death. In the 
absence of its beta subunit, DT is unable to penetrate cells, limiting the nonspecific induction 
of cell death in neighboring cells. Targeting the expression of the DT to oligodendrocytes is 
achieved using Cre/LoxP technology using a major myelin protein promoter, and its activation 
is through tamoxifen-induced removal of transcriptional stop sequences resulting in death of 
oligodendrocytes. One interesting finding from these studies is that extensive loss of oligo-
dendrocyte cell bodies is not correlated with rapid myelin loss. After a post-treatment delay of 
approximately 3 weeks, the mice displayed progressive motor deficits associated with signifi-
cant myelin degradation and vacuolization. A second unexpected outcome of these studies 
was that the widespread loss of oligodendrocytes did not trigger a rapid immune response. 
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While remyelination was extensive, and the animals appeared to recover completely with 
longer survival times, recovery was compromised and there was an infiltration of T cells into 
the CNS. Adoptive transplantation of these T cells into naïve hosts was sufficient to transfer 
disease. It is likely that the initial insult served to prime the immune system, which eventually 
led to an autoimmune response and subsequent CNS demyelination [69].
The DT model also differs from MS in a number of key ways. As discussed above, MS is a 
spontaneous disease, and the lesions develop in a variable manner in both time and space. 
MS is also not toxin-induced, although there might be a role for pathogens in initial disease 
stages. The cell death model, on the other hand, depends on the use of a toxin that effectively 
terminates protein translation, causing cell ablation, and subsequent recruitment of phago-
cytic cells. Another key difference between the two is that the clearance of myelin in MS fol-
lowing oligodendrocyte loss is rather rapid and is driven by both resident and peripheral 
immune cells. In contrast, myelin clearance is clearly delayed in the DT model, which would 
indicate that it is either inhibited or nonexistent. A major concern for the DT model is the 
complete nature of oligodendrocyte loss, which differs significantly from the focal loss of 
oligodendrocytes in MS.
In a related model, the specificity of the toxic insult is targeted through receptor expression in 
a null background [70]. For example, expression of the DT receptor (DTR) under the control 
of an oligodendrocyte-specific promoter results in cell type sensitivity to diphtheria toxin. 
Exposure to DT results in the induction of cell death by inhibiting protein synthesis. The clini-
cal phenotype includes ataxia, limb paralysis, and tail spasticity that appear around 10 days 
post-injection and progressively develop. Perturbations in somatosensory evoked potentials 
together with histological markers of neurodegeneration, and abnormal Nodes of Ranvier 
indicate dysfunctional neural networks. The pathology differs between the models; while the 
DT mice display severe demyelination, the DTR mice show little demyelination. This may 
reflect that in the DTR model, there is a more extensive engagement of axonal damage leading 
to death before demyelination develops.
A potential strength of the DTR model is that it may provide a model system to examine the 
mechanisms and develop targeted therapies against axonal damage in demyelinating dis-
eases since axonopathy is a frequent pathological finding in MS.
During CNS development, many cell types including oligodendrocytes are produced in 
excess and the additional cells are eliminated through apoptosis-mediated cell death. Cell 
type-specific induction of apoptosis through activation of an inducible caspase 9 construct 
driven off a selective promoter has been used to specifically eliminate lymphocytes and oli-
godendrocytes [71]. Induction of oligodendrocyte apoptosis in the adult CNS results in rapid 
demyelination and local activation of microglia in the absence of T cell infiltration [72, 73]. 
During development, activation of oligodendrocyte apoptosis in the first postnatal week 
inhibits myelination, which subsequently recovers but has increased susceptibility to adult 
insults [72]. The role of oligodendrocyte apoptosis in early stages of MS is not well defined; 
however, apoptotic oligodendrocytes have been reported in the early lesions [74], suggesting 
this may contribute to MS plaque formation. Similarly, activated microglia but an absence of 
peripheral immune cells has been described in some early lesions.
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Overall, while models of selective oligodendrocyte death have provided important insights 
into the response of the neural cells and the pathway of myelin loss, they have not yet been 
used to identify new pathways of pathology or illuminate new targets for therapeutic inter-
ventions. Whether they will provide a useful platform for the development of therapies for 
distinct subsets of MS awaits further refinement and analysis.
2.4. In vitro discovery platforms for therapeutic development
Over the past decade, there has been significant development of new platforms for remyelin-
ation drug discovery. These include the use of isolated purified cell preparations, rodent IPS 
cells that provide an unlimited supply of cells, human cell line-derived neural cells, human 
IPS cells, and in silico model systems. Each of these platforms has its own advantages and 
disadvantages. In general, such in vitro approaches have been relatively powerful in identify-
ing pathways that regulate myelin formation from mature oligodendrocytes but have been 
less effective at identifying signaling pathways that regulate the proliferation and survival of 
oligodendrocytes and their precursors.
With the development of culture models for CNS neural cells and the ability to unambig-
uously identify distinct cell populations, the ability to identify molecular signaling that 
promoted the development of oligodendrocytes was feasible. Early studies utilized mixed 
cultures derived from either white matter such as the optic nerve, mixed gray and white mat-
ter such as the spinal cord or predominantly grey matter such as cerebral cortex. Addition of 
selected growth factors or other signaling molecules that resulted in an increase in mature 
oligodendrocytes was considered potential therapy. There are two major concerns with this 
approach. First, the cellular target(s) of the added molecules is unclear, since the culture con-
tains not only cells of the oligodendrocyte lineage but also astrocytes, neurons, and innate 
immune cells of the CNS, any of which might mediate the response. The second concern 
is that increased numbers of mature oligodendrocyte may result from either enhanced pro-
genitor proliferation, reduced cell death, or increased cell differentiation, and distinguishing 
between these mechanisms has proven challenging. To refine the cellular target(s) of potential 
therapeutics, purified cell cultures have been utilized. Purification of rodent or murine OPCs 
either through differential antibody binding (panning) or FACS sorting allows for assessment 
of the direct response of the cell population to therapeutic exposure. Such approaches have 
been used recently to identify signaling mechanisms that promote the appearance of mature 
oligodendrocytes [75–78]. One concept that has gained significant support in recent years is 
the notion that the rate-limiting step in remyelination is the differentiation and maturation of 
oligodendrocytes to myelinating cells. Several more refined approaches have been developed 
to identify factors that directly regulate oligodendrocyte maturation. These include the use 
of purified OPCs initially derived from human material. The emergence of IPS technology 
combined with identification of molecular environments that promote the survival of human 
cells has facilitated the identification of several small molecules that mediate oligodendrocyte 
maturation such as retinoic receptors, benztropine and miconazole. In the majority of such 
screens, the readout has been enhanced by expression of myelin proteins such as MBP. While 
this has proven useful, the ultimate goal of remyelinating therapies is the generation of new 
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myelin. Recent studies have used a biophysical approach to identify signals that promote the 
formation of myelin on artificial substrates. When grown in the presence of inert fibers of the 
appropriate dimensions, oligodendrocytes will begin to enwrap them as if they were imma-
ture axons. Molecules that enhance that process are considered strong candidate to promote 
remyelination in the CNS, and molecules including Clemastine an anti-histamine drug have 
been identified in similar assays.
While the reductionist approaches provide important insights into isolated cellular responses 
of the oligodendrocyte lineage, they lack any physiological setting. As a result, it is unclear 
whether signals that modulate oligodendrocyte maturation in isolation will promote myelin 
repair in the developing or diseased CNS. One model to address this concern is the use of slice 
cultures. Slices of the CNS grown on the air/medium interface develop robust myelination. 
The most successful slices are those derived from cerebellum and coronal sections through 
the corpus callosum. Treatment of such slices with LPC results in rapid demyelination and 
allows for analysis of drug-induced repair in an efficient and physiological environment. In 
most studies, multiple different models are used to determine the efficacy individual com-
pounds to promote remyelination.
3. Conclusions and comments
There is a broad range of animal models that address distinct aspects of multiple sclerosis 
and other demyelinating diseases. Each of the models has specific strengths and weaknesses 
in furthering our understanding of the pathogenic processes that mediate demyelination and 
in identifying new opportunities for the effective promotion of myelin repair. EAE models 
have led to the development of many therapeutic targets aimed at halting disease progres-
sion. More recently, other models such as those targeting oligodendrocyte cell death have 
been instrumental in fine-tuning our understanding of the pathology of demyelination/
remyelination in MS and other similar diseases. Each of the model systems discussed in this 
review deserves particular credit, as it has helped solve a different piece of the puzzle. For 
example, while EAE models have unraveled many of the immunological bases of the CNS 
demyelination, particularly the role of T cells in MS, the use of glial toxins such as LPC or 
ethidium bromide has emerged as extremely useful in reshaping our understanding of the 
environmental and cell-based mechanisms of remyelination, and the models of oligodendro-
cyte death provide insights into factors driving the pathology. It seems likely that new mod-
els will be forthcoming that more effectively address the role of cells other than those of the 
immune and oligodendrocyte lineage. Understanding the role of microglia and astrocytes, as 
well as further clarity around the mechanism of vascular components in disease progression, 
will allow new therapeutic avenues to be developed in future studies.
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